See more : Econocom Group SE (ECONB.BR) Income Statement Analysis – Financial Results
Complete financial analysis of TC Biopharm (Holdings) Plc (TCBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TC Biopharm (Holdings) Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Federal Home Loan Mortgage Corporation (FMCCI) Income Statement Analysis – Financial Results
- Ibstock plc (IBJHF) Income Statement Analysis – Financial Results
- Anglo Pacific Group plc (APY.TO) Income Statement Analysis – Financial Results
- Stockland (STKAF) Income Statement Analysis – Financial Results
- The Navakij Insurance Public Company Limited (NKI.BK) Income Statement Analysis – Financial Results
TC Biopharm (Holdings) Plc (TCBP)
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.77M | 7.59M | 6.16M | 6.68M | 8.61M |
| General & Administrative | 6.47M | 8.34M | 3.11M | 2.21M | 3.01M |
| Selling & Marketing | 402.31K | 402.31K | 0.00 | 0.00 | 0.00 |
| SG&A | 6.87M | 8.74M | 3.11M | 2.21M | 3.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Cost & Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Interest Income | 83.03K | 6.75M | 3.44M | 291.03K | 253.51K |
| Interest Expense | 0.00 | 6.75M | 3.44M | 292.06K | 275.41K |
| Depreciation & Amortization | 630.06K | 762.47K | 811.96K | 878.64K | 721.93K |
| EBITDA | -13.61M | -11.32M | -6.48M | -5.26M | -5.92M |
| EBITDA Ratio | 0.00% | -294.48% | -327.25% | -303.65% | -172.71% |
| Operating Income | -14.24M | -12.08M | -7.29M | -6.89M | -6.64M |
| Operating Income Ratio | 0.00% | -314.32% | -368.28% | -348.05% | -193.78% |
| Total Other Income/Expenses | 7.24M | 9.05M | -7.70M | -291.03K | -253.51K |
| Income Before Tax | -7.00M | -3.03M | -14.98M | -6.63M | -6.89M |
| Income Before Tax Ratio | 0.00% | -78.91% | -757.25% | -335.07% | -201.18% |
| Income Tax Expense | -1.09M | 1.72M | 1.41M | 1.17M | 826.07K |
| Net Income | -5.91M | -1.31M | -13.58M | -5.46M | -6.07M |
| Net Income Ratio | 0.00% | -34.17% | -686.12% | -275.84% | -177.07% |
| EPS | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| EPS Diluted | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| Weighted Avg Shares Out | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
| Weighted Avg Shares Out (Dil) | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025 EDINBURGH, Scotland , Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or...
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has...
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its...
TCBP Responds to False Social Media Claim
TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange EDINBURGH, Scotland , Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing...
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
EDINBURGH, Scotland , Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered...
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could have additional applications across cell therapy for donor/patient matching EDINBURGH,...
TCBP Announces Site Opening of Guys and St. Thomas Hospital
Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland , Sept. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
TCBP to Present at the 2024 ThinkEquity Conference in NYC
EDINBURGH, Scotland , Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer...
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or...
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
EDINBURGH, Scotland , Sept. 9, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to...
Source: https://incomestatements.info
Category: Stock Reports